Thread by @aishaikh

💥Drug-Coated Balloons for Dysfunctional Arteriovenous Fistulas
@NEJM

‼️Drug-coated balloon (DCB) angioplasty was superior to standard balloon angioplasty for stenotic lesions in the AVF at 6-months (82% vs. 59.5%)
👉🏽 nejm.org/doi/full/10.10…

@ASDINNews
1/

💥Type of AVFs in the study👇🏽

~ 50% Radial-cephalic
~ 36% Brachial-cephalic
~ 10% Brachial-basilic
2/

💥Site of the stenotic lesions in the AVF in this study👇🏽

⚡️Venous Outflow stenosis: 32%
⚡️Arteriovenous anastomosis: 25.5%

No central vein stenosis and in-stent stenotic lesions included in this study
3/

💥Target lesion patency at 6 months:
⚡️DCB angioplasty: 82%
⚡️Standard balloon angioplasty: 59.5%
‼️Difference: 22.8%

💥Primary access circuit patency better at 6-months w/ DCB angioplasty vs. Standard balloon angioplasty
73% vs. 48%
‼️Difference: 25%
4/

💥DCB vs. Standard Balloon Angioplasty

⚡️No difference in access circuit thrombosis are 6 months
⚡️No difference in adverse events within 30 days
⚡️No difference in mortality at 1-year
5/

💥How is this DCB study different from the prior DCB study in AVF pts. published in @CJASN which reported NO improvement in primary access patency w/ DCB?
👉🏽cjasn.asnjournals.org/content/clinja…

Paclitaxel dose: 2.2 vs.3.5 micrograms per mm2 (higher dose in NEJM study)
6/

💥This DCB Study is a significant step forward in improving AVF patency but long term follow-up for AVF patency and long term safety data (mortality data beyond 12 months) will help advance our understanding of DCB use in ESKD patients with AVF

End/